Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder

Pharmaceuticals

Rubo J. Seo¹  Holly MacPherson¹ 

[1] Institute of Mental Health, Department of Psychiatry, University of British Columbia, 5950 University Blvd. Vancouver, BC V6T 1Z3, Canada;

关键词: treatment resistant disorder;    major depressive disorder;    augmentation;    atypical antipsychotic;    typical antipsychotic;    antidepressant;    selective serotonin reuptake inhibitor;    electroconvulsive therapy;   

DOI  :  10.3390/ph3123522

来源: mdpi

【 摘 要 】

Antidepressant therapies, such as selective serotonin reuptake inhibitors (SSRIs), are current first-line treatments for Major Depressive Disorder. However, over 50% of treated patients show an inadequate response to initial antidepressant therapy. If the therapeutic outcomes from two antidepressant therapies are suboptimal, potentially resulting in Treatment Resistant Depression, subsequent strategies include switching to another antidepressant or augmenting treatment by combining with other agents. When combined with SSRIs, atypical antipsychotics have supplementary action on dopaminergic and noradrenergic systems. Studies on combined treatment with atypical antipsychotics have shown significantly increased remission rates, shortened response times, and favorable side effects. Augmentation of antidepressants with atypical antipsychotics is now an acceptable treatment strategy which leads to increased remission rates and better outcomes for patients.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.